Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | August 31, 2023 | September 01, 2023 |
| PRF Technologies Ltd.PRFX · Entity 8440 | Director | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 31, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series Y Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 24.573 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
| Series Y Preferred StockSEC Table I · non-derivative | IndirectBy The Lawlor Family Trust UAD 4-17-00 | 0 |
Reported balance
After 2023-08-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-31 · Disposition to issuer · Disposed 24.215 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.
PRF Technologies Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5,400.00 · Expires 2031-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F2: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.00 · Expires 2034-07-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Options granted under the 2019 PainReform Option Plan. F3: The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2019 PainReform Option Plan.
F2: The grant date of this grant is February 23, 2021. This option grant is fully vested as of this date.
F3: The grant date of this grant is July 18, 2024. 160 of the options were vested as of the date of appointment. The remaining 23 options will vest in two quarterly installments occurring on April 18, 2026 and July 18, 2026, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CYPHERPUNK TECHNOLOGIES INC.
Report date June 30, 2025 · Filed July 01, 2025
Section 16 reporting ended · disclosed 2025-07-01. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Cardiovascular Systems Inc
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 5,022 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy Lawlor Family Trust | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-04-27 · Disposition to issuer · Disposed 25,318 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 103,719 · Balance 0 F2: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2025 Filed Apr 2, 2025 01:53 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person. F6 · derivative.exercise_date: The January 2022 RSUs became fully vested on January 31, 2025 but settlement thereof was deferred by the Compensation Committee of the Board of Directors of the Company until March 28, 2025 pursuant to, and in accordance with, the terms of the January 2022 RSUs, which terms provide that the Compensation Committee would have the authority to defer the settlement of the January 2022 RSUs to a date later than the vesting date of the January 2022 RSUs in the event that on such vesting date the reporting person were to be subject to, among other things, any limitation or restriction under the Company's insider trading policy that would not permit the reporting person to sell on such vesting date all of the shares of the Company's Common Stock underlying the January 2022 RSUs if the January 2022 RSUs were to be settled on such vesting date. F7 · derivative.exercise_date: The Compensation Committee of the Board of Directors took action to defer settlement of the January 2022 RSUs so that such settlement would not occur on January 31, 2025, the vesting date thereof. The January 2022 RSUs were settled on March 28, 2025 on a net issue basis as further described on note (2) above. F8 · derivative.expiration_date: The terms of the January 2022 RSUs provide that the January 2022 RSUs would automatically terminate and be forfeited upon termination of the reporting person's employment or other service relationship with the Company if such termination of employment or service relationship were to occur at any time prior to January 31, 2022, the vesting date of the January 2022 RSUs. Read SEC document |
| March 28, 2025 Filed Apr 2, 2025 01:53 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Tax withholdingCommon Stock | 7,797 | $0.32 | $2,468.53 |
DisclosureSEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · nonDerivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,789 F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person. F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. Read SEC document |
| March 28, 2025 Filed Apr 2, 2025 01:53 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-030808 · tm2511110-6_4seq1.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 22,500 Restricted Stock Units previously granted by the Company to the reporting person on January 31, 2022 (the "January 2022 RSUs") were settled on March 28, 2025 on a net issue basis such that, of the 22,500 shares of the Company's common stock underlying the January 22 RSUs, the Company issued to the reporting person on such settlement date only 14,703 of such shares and the Company withheld on such settlement date the remaining 7,797 of such shares in order to satisfy tax withholding obligations in connection with the settlement of the January 2022 RSUs. None of such 7,797 shares of the Company's common stock so withheld by the Company constituted sales of such shares by the reporting person. F3 · price: Each of the January 2022 RSUs represented a contingent right to receive one share of the Company's Common Stock. F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 22:29 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | OtherWarrant (Right to Buy) · Derivative | 2,136 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001104659-24-119793 · tm2428586-2_4seq1.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 2,136 shares Expires 2024-11-14 F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock. F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 22:29 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | OtherCommon Stock | 2,136 | $2.82 | $6,023.52 |
DisclosureSEC source: 0001104659-24-119793 · tm2428586-2_4seq1.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 678,456 F1 · kind: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock. F2 · balance_after: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is the manager and a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust. F3 · balance_after: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock. F1 · ownership.nature: On November 13, 2024, Nine Capital Partners, LLC ("Nine Capital Partners") exercised a warrant to purchase 2,136 shares of the Issuer's common stock at an exercise price of $2.82 per share. The reporting person is a managing member of Nine Capital Partners and may be deemed to have had beneficial ownership of such warrant exercised by Nine Capital Partners and to have beneficial ownership of the 2,136 shares of Common Stock purchased by Nine Capital Partners upon exercise of such warrant. The reporting person disclaims beneficial ownership of such warrant and of such shares of Common Stock, except to the extent of the reporting person's proportionate pecuniary interest in such warrant and such shares of Common Stock. F2 · ownership.nature: Includes (i) 2,136 shares of Common Stock held by Nine Capital Partners, (ii) 414,480 shares of Common Stock held by HealthCare Ventures IX, L.P. ("HCV IX"), and (iii) 261,840 shares of Common Stock held by the HCV VIII Trust ("HCV Trust"). See footnote (1) above for an explanation of the reporting person's beneficial ownership of the 2,136 shares of Common Stock held by Nine Capital Partners. The reporting person is a Managing Director of HCPIX LLC, which is the General Partner of HealthCare Partners IX, which is the General Partner of HCV IX and may be deemed to have beneficial ownership of the 414,480 shares of Common Stock held by HCV IX. The reporting person is the manager and a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust. F3 · ownership.nature: The reporting person disclaims beneficial ownership of such shares of Common Stock held by each of Nine Capital Partners, HCV IX, and the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:24 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-106335 · tm2425653-4_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of October 2, 2024. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 02:34 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-24-009022 · tm244775-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-01-29 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of January 29, 2024. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 01:38 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-008418 · tm244628-2_4seq1.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit. F5 · derivative.expiration_date: On January 26, 2021, the reporting person was granted 5,000 Restricted Stock Units, vesting on January 26, 2024 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 01:38 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-008418 · tm244628-2_4seq1.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis. F2 · balance_after: The share numbers reflected in Tables I and II have been adjusted to take into account a 10-for-1 reverse stock split of the Company's common stock that was effected on June 20, 2023. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 24.215 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042365 · form4.xml · nonDerivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Lawlor Family Trust UAD 4-17-00 Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 24.573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042365 · form4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:31 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001104659-23-095365 · tm2324823-11_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2033-08-23 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan, as amended. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on September 23, 2023 and an additional of such monthly installments vesting on the 23rd day of each calendar month thereafter. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 16:34 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | Disposition to issuerRestricted Stock Units · Derivative | 103,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-009600 · form4.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,719 shares Expires not disclosed F2 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes. F2 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 16:34 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | Disposition to issuerCommon Stock | 25,318 | $20.00 | $506,360.00 |
DisclosureSEC source: 0001062993-23-009600 · form4.xml · nonDerivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Lawlor Family Trust Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 16:34 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | Disposition to issuerCommon Stock | 5,022 | $20.00 | $100,440.00 |
DisclosureSEC source: 0001062993-23-009600 · form4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each share of common stock converted pursuant to the Merger Agreement into the right to receive $20.00 in cash per share, without interest and less any required withholding taxes. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:09 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-23-041741 · tm2311741-1_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of March 31, 2023, the Vesting Start Date. Read SEC document |
| September 01, 2022 Filed Sep 3, 2022 01:26 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001104659-22-097619 · tm2225099-8_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2022 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of September 1, 2022, the Vesting Start Date. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:18 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 9,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019615 · rdgdoc.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,064 Underlying: Common Stock · 9,064 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 2,266 shares on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023. F2 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 2,266 shares on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023. F2 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 2,266 shares on each of September 30, 2022, December 31, 2022, March 31, 2023 and June 30, 2023. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 02:49 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantRestricted Stock Units · Derivative | 225,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011055 · tm225302-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F1 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F2 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 16:36 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000411 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022 F1 · shares: Represents fully vested restricted stock received at the election of the reporting person, in lieu of cash payment, as additional retainer for service as a director of the Company during fiscal year 2022. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 5,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059429 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,573 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 19:19 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 3,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000245 · edgar.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,814 Underlying: Common Stock · 3,814 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 954 shares on each of September 30, 2021 and December 31, 2021 and as to 953 shares on each of March 31, 2022 and June 30, 2022. F4 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 954 shares on each of September 30, 2021 and December 31, 2021 and as to 953 shares on each of March 31, 2022 and June 30, 2022. F4 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 954 shares on each of September 30, 2021 and December 31, 2021 and as to 953 shares on each of March 31, 2022 and June 30, 2022. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 19:19 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000245 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 F1 · shares: Represents restricted stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a director of the Company during fiscal year 2022. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 13:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 5,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044690 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,734 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044690 · doc4.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:33 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001104659-21-074446 · tm2117938-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of May 26, 2021, the Vesting Start Date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:38 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 4,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025032 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,192 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 13:55 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | Tax withholdingWarrant (Right to Buy) · Derivative | 11,544 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021299 · tm216410-5_4seq1.xml · derivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,544 Underlying: Common Stock, $0.001 par value per share · 11,544 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F4 · ownership.nature: These warrants were acquired by Nine Capital Partners, LLC ("Nine Capital Partners"), a limited partner of HCVIX, in connection with the Transfer. The reporting person is a member of Nine Capital Partners and may be deemed to indirectly beneficially own and share voting and dispositive power with respect to all securities held by Nine Capital Partners. The reporting person disclaims beneficial ownership of the warrants except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 13:55 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | OtherWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-21-021299 · tm216410-5_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F1 · kind: On February 9, 2020, HealthCare Ventures IX, L.P. ("HCVIX") transferred, for no consideration, all 571,428 warrants to purchase common stock it held (the "Transfer") to the limited partners of HCVIX on a pro rata basis. The term of HCVIX expired on December 31, 2020, at which time HCVIX entered into liquidation. The process of liquidating HCVIX, including the distribution of marketable and non-marketable securities, has commenced in 2021, and HealthCare Partners IX, L.P. ("HCPIX"), the General Partner of HCVIX, as liquidator, will use its best efforts to complete the orderly liquidation of HCVIX. F2 · kind: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. F3 · price: The warrants were acquired in connection with the purchase of an equal number of shares of common stock by HCVIX on February 5, 2019 for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. HCVIX will continue to hold 4,144,804 shares of common stock following the Transfer. F2 · ownership.nature: These warrants were owned directly by HCVIX. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HCPIX, which is the General Partner of HCVIX. Each of the HCVIX Directors, HCPIX LLC and HCPIX indirectly beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCVIX, and each disclaimed beneficial ownership of the warrants except to the extent of his or its proportionate pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:55 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-008992 · tm214605-3_4seq1.xml · derivative · entry 2 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F2 · price: The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock. F3 · derivative.exercise_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. F3 · derivative.expiration_date: The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 02:55 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001104659-21-008992 · tm214605-3_4seq1.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of January 26, 2021, the Vesting Start Date. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:57 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002162 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,431 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:19 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 5,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053123 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,014 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| August 10, 2020 Filed Aug 13, 2020 01:19 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001104659-20-094201 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-08-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one month anniversary of August 10, 2020, the Vesting Start Date. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 17:13 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 4,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000264 · edgar.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,661 Underlying: Common Stock · 4,661 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,166 shares on September 30, 2020 and 1,165 shares on each of December 31, 2020, March 31, 2021 and June 30, 2021. F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,166 shares on September 30, 2020 and 1,165 shares on each of December 31, 2020, March 31, 2021 and June 30, 2021. F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 1,166 shares on September 30, 2020 and 1,165 shares on each of December 31, 2020, March 31, 2021 and June 30, 2021. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 17:13 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 2,090 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000264 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,408 F1 · shares: Represents restricted stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a director of the Company during fiscal year 2021. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:43 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040391 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,215 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:46 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036313 · doc4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 09, 2020 Filed Apr 14, 2020 00:19 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001104659-20-046072 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-04-09 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of April 9, 2020, the Vesting Start Date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:40 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 4,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023187 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,542 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 21:21 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | SaleCommon Stock | 69,401 | $6.10 | $423,505.72 |
DisclosureSEC source: 0001209191-20-012454 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By HealthCare Ventures VIII, L.P. Disclosed balance after: 0 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $6.10 to $6.22 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · ownership.nature: HealthCare Ventures VIII, L.P. ("HCVVIII") is the registered owner of the securities. The Reporting Person is a managing director of HealthCare Partners VIII, LLC ("HCPVIII LLC"), the General Partner of HealthCare Partners VIII, L.P. ("HCPVIII"). HCPVIII is the General Partner of HCVVIII. The Reporting Person shares voting and investment power over the shares held by HCVVIII with each of Christopher Mirabelli, James Cavanaugh, John Littlechild and Harold Werner as managing directors of HCPVIII LLC. The Reporting Person disclaims beneficial ownership of those securities in which he does not have a pecuniary interest and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein. Read SEC document |
| January 02, 2020 Filed Jan 2, 2020 21:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 3,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000340 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,608 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:08 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 4,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051620 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,442 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 17:17 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantRestricted Stock Units · Derivative | 3,088 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000289 · edgar.xml · derivative · entry 3 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,088 Underlying: Common Stock · 3,088 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 772 shares on each of September 30, 2019, December 31, 2019, March 31, 2020 and June 30, 2020. F3 · derivative.exercise_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 772 shares on each of September 30, 2019, December 31, 2019, March 31, 2020 and June 30, 2020. F3 · derivative.expiration_date: Each restricted stock unit represents the right to receive a payment from the Company equal in value to the market price per share of Company common stock on the date of payment and shall be payable in cash or shares of Company common stock beginning six months following the termination of the reporting person's board membership; provided, however, that the restricted stock units vest in quarterly amounts of 772 shares on each of September 30, 2019, December 31, 2019, March 31, 2020 and June 30, 2020. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 17:17 UTC | Cardiovascular Systems Inc CSII · Entity 114141 | GrantCommon Stock | 1,810 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000289 · edgar.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,318 F1 · shares: Represents restricted stock received at the election of the reporting person, in lieu of cash payment, as a retainer for service as a director of the Company during fiscal year 2020. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:50 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040360 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,051 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:17 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001209191-19-037572 · doc4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2019. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 20:45 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-19-035079 · a4.xml · derivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The Option was granted pursuant to Leap's 2016 Equity Incentive Plan and shall vest and become exercisable in a series of 36 equal monthly installments until the Option is fully vested, with the first such monthly installment vesting on the one-month anniversary of June 11, 2019, the Vesting Start Date. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:38 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022537 · doc4.xml · nonDerivative · entry 1 LAWLOR AUGUSTINE · CIK 0001262327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,146 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| February 05, 2019 Filed Feb 5, 2019 21:21 UTC | CYPHERPUNK TECHNOLOGIES INC. LPTX · Entity 6392 | PurchaseWarrant (Right to Buy) · Derivative | 571,428 | Not disclosed Strike: $1.95 | Not disclosed |
DisclosureSEC source: 0001104659-19-005837 · a4.xml · derivative · entry 4 LAWLOR AUGUSTINE · CIK 0001262327 · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 592,797 Underlying: Common Stock, $0.001 par value per share · 571,428 shares Expires 2026-02-05 F4 · price: The reported securities were included with the 571,428 shares of common stock purchased by HealthCare Ventures IX, L.P. for $1.75 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock. F1 · ownership.nature: The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. ("HCPIX"), which is the General Partner of HealthCare Ventures IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.